Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Abstract

First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy. (UMIN-CTR number, C000000376.)